NASDAQ$THRD
Third Harmonic Bio Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced third quarter 2022 financial results and provided a corporate update.
Third Harmonic Bio reported a net loss of $8.2 million for the quarter ended September 30, 2022. They completed an upsized initial public offering, providing funding through 2025, and patient dosing is underway in a Phase 1b chronic inducible urticaria clinical trial.
- Completed an upsized $213.1 million initial public offering.
- Patient dosing is underway in a Phase 1b trial in Chronic Inducible Urticaria.
- The company expects to initiate a Phase 1b clinical trial in asthma during the first half of 2023.
- Initial clinical data from its Phase 1b proof-of-concept clinical trial in chronic inducible urticaria will be reported during the second half of 2023.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Forward guidance
Third Harmonic Bio expects to achieve several milestones in the coming years, including submitting a clinical trial application in Canada for THB001, reporting initial clinical data from its Phase 1b proof-of-concept clinical trial in chronic inducible urticaria, submitting both a CTA in Europe and an investigational new drug application in the United States to support the initiation of a Phase 2 trial in chronic spontaneous urticaria, and reporting initial data from the Phase 1b asthma trial.
Tailwinds
- Submit a clinical trial application (CTA) in Canada for THB001 to support the initiation of a Phase 1b trial in asthma during the first half of 2023.
- Report initial clinical data from its Phase 1b proof-of-concept clinical trial in chronic inducible urticaria during the second half of 2023.
- Submit both a CTA in Europe and an investigational new drug application in the United States to support the initiation of a Phase 2 trial in chronic spontaneous urticaria in the first half of 2024.
- Report initial data from the Phase 1b asthma trial in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro